Recently, a retrospective study found that the percentage of LXRα-positive cells in stage II non-small cell lung cancer (NSCLC) patients was higher than that in stage III NSCLC patients (58% vs. 41%, p  = 0.04), indicating that LXRα might be an influential factor in the TNM staging system for further improving NSCLC treatment [88]. The gene discussed is NR1H3; the disease is non-small cell lung carcinoma.